The subconjunctival implant of dexamethasone reduces the risk of graft rejection after penetrating keratoplasty.

Published Date: 17 Mar 2023

Dexamethasone subconjunctival implant may be safe and effective in preventing infection in patients after infiltration with a low risk of rejection...

Read Full News

Latest News

Endophthalmitis a Risk for Years After Tube Shunt Surgery

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Trabeculectomy Often More Cost-Effective Than Tube Shunts

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

Common Epilepsy Drug Tied to Increased Glaucoma Risk

Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.

Worsening Heart-Kidney-Metabolic Health May Threaten Vision

People with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.

Study Maps Extensive Disease Links Beyond Childhood Eczema

Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.

Neoadjuvant Therapy Use Rising Sharply in Cancer Care

The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.

Todays Updates

Have the Harms of Lung Cancer Screening Been Exaggerated?

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Todays Updates

Have the Harms of Lung Cancer Screening Been Exaggerated?

Three medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.

Pretreatment Liver Tests Often Overlooked in CDK4/6 Therapy

Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.

Alternative Medicine for Breast Cancer: Study Raises Concern

Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.

Latest News

The risk for endophthalmitis after glaucoma drainage rises for up to 5 years and is much higher than that for a device-placement surgery for detached retina, a study finds.

Analysis of data from a randomized trial finds trabeculectomy typically is the better financial bet than tube shunt surgery as a first option to treat glaucoma.

Use of topiramate is linked to a higher risk for glaucoma than valproate or lamotrigine, especially in women and patients with epilepsy, new research shows.

People with worsening cardiovascular-kidney-metabolic syndrome may face an increased risk for developing age-related macular degeneration.

Using millions of NHS records, researchers mapped extensive links between childhood eczema and later inflammatory and eye diseases.

The second annual NCDB report reveals a major shift toward preoperative systemic therapy in solid tumors, offering new opportunities for de-escalation, although careful patient selection is needed.

News All Time

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

FDA Issues Complete Response Letter for ONS-5010 for Wet AMD

Ophthalmology in 2025: Year in Review

Ophthalmology in 2025: Year in Review

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

New Parameters for Faster Geographic Atrophy Progression Established, with Srinivas Sadda, MD Srinivas Sadda, MD

The pooled sham cohorts of the OAKS and DERBY trials have revealed a series of indicators for faster geographic atrophy lesion growth.

OCU-410 Gene Therapy Preserves Visual Acuity and Slows GA Lesion Progression, with Jay Chhablani, MD Jay Chhablani, MD

Recent phase 1/2 trial data indicate the safety and efficacy of the surgical, subretinal injection in monitoring cellular homeostasis.

Intravitreal UBX1325 Shows Efficacy in Diabetic Retinopathy, DME, with Dante Pieramici, MD Dante J. Pieramici, MD

Results from the BEHOLD and ASPIRE trials indicate the long lasting effects of UBX1325 in improving retinal function and structure.

Psoriasis Associated with Risk of Age-Related Macular Degeneration Ryan Livingston

Based on 3 propensity-matched control groups, patients with psoriasis can have anywhere from a 40% to 56% higher risk.

Correlation Between Diabetes and Risk of Uveitis Confirmed in Recent Study Ryan Livingston

In addition to type 1 and 2 diabetes, diabetic retinopathy substantially increases the risk of developing and worsening uveitis.

Q3 2025 Recap: Ophthalmology News and Updates Ryan Livingston

The Q3 recap for ophthalmology spotlights major FDA decisions and major clinical trial updates in a variety of diseases.

FDA Approves Incision-Free Topical Therapy Epioxa for Keratoconus Ryan Livingston

This approval represents an alternative method for approaching this undertreated disease, shortening recovery while minimizing invasiveness.

Dyslipidemia May Delay Macular Hole Closure After Surgery Ryan Livingston

A recent study highlights correlations between later healing, triglyceride levels, and total cholesterol in patients receiving MH.

FDA Approves Adalimumab-aaty (Yuflyma) Pediatric Indications in Hidradenitis Suppurativa, Uveitis Abigail Brooks, MA

The FDA approved expanded indications for adalimumab-aaty (Yuflyma) and its unbranded version to include the treatment of adolescent HS and pediatric UV.

GLP-1 RAs May Influence Development of Nonexudative AMD in Patients With Obesity Ryan Livingston

Although no direct correlation can be drawn, these findings suggest a possible ocular benefit from GLP-1 RAs compared to other weight loss drugs.

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

Brolucizumab Outperforms Aflibercept in DME Regardless of Prior Treatment

Recommended News For You

The need for more Latinx participants in Alzheimer's trials is urgent.

Cancer Vaccines' Emergence; More Focus on Side Effects; A Nudge for Exercise.

The First Gene Therapy Provides a Durable Response for Non-Muscle-Invasive Bladder Cancer.

Anticoagulation for 12 months has been found to improve outcomes in cancer patients with minor blood clots.

Genetics and Genetic Testing to Inform Myelofibrosis Clinical Management.

Xerostomia in Head and Neck Cancer Patients Can Be Predicted by Mid-Treatment PET/CT Scans.

Oncology Drug Shortages Persist, but Continue to Evolve

Recommended Articles For You

Uncovering Dyscrasia: A Comprehensive Guide to Diagnosis and Treatment 

The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology 

The Journey Beyond Treatment: Empowering Cancer Survivorship with Technology and Artificial Intelligence 

The Importance of Early Detection in Angiosarcoma: A Story of Survival  

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker Flags 10-Fold Recurrence Risk in Testicular Cancer

2.

Prostate cancer screening program beneficial in top decile of polygenic risk score

3.

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

4.

Immunotherapy-TACE Regimen Boosts PFS in Unresectable Liver Cancer

5.

Rising rates of head and neck cancers in England

1.

Exploring the Mysteries of Myxoma: A New Frontier in Medical Research

2.

The Rise of Immunotherapy: New Advances in Cancer Treatment

3.

The Basics of Langerhans Cell Histiocytosis: Understanding a Rare Disease 

4.

Enhancing Cancer Care: From Diagnosis Through Survivorship and Beyond

5.

Symptoms and Causes of Phlegmasia Cerulea Dolens: A Comprehensive Guide 

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V

2.

A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

3.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)

4.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II

5.

First Line Combination Therapy- The Overall Survival Data in NSCLC Patients


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot